Kazia Therapeutics (KZIA) Accumulated Expenses (2017 - 2025)

Kazia Therapeutics' Accumulated Expenses history spans 6 years, with the latest figure at $249768.9 for Q2 2025.

  • For Q2 2025, Accumulated Expenses rose 3.84% year-over-year to $249768.9; the TTM value through Jun 2025 reached $249768.9, up 3.84%, while the annual FY2025 figure was $249768.9, 3.84% up from the prior year.
  • Accumulated Expenses reached $249768.9 in Q2 2025 per KZIA's latest filing, up from $240543.9 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $461168.7 in Q2 2023 to a low of $145402.5 in Q2 2022.
  • Average Accumulated Expenses over 4 years is $274221.0, with a median of $245156.4 recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 217.17% in 2023, then crashed 47.84% in 2024.
  • A 4-year view of Accumulated Expenses shows it stood at $145402.5 in 2022, then surged by 217.17% to $461168.7 in 2023, then crashed by 47.84% to $240543.9 in 2024, then increased by 3.84% to $249768.9 in 2025.
  • Per Business Quant, the three most recent readings for KZIA's Accumulated Expenses are $249768.9 (Q2 2025), $240543.9 (Q2 2024), and $461168.7 (Q2 2023).